NDA 215429 · Almatica
Venlafaxine Besylate
Venlafaxine Besylate · Oral
Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Jun 29, 2022
Approved uses
2
Original approval plus efficacy supplements
Registered trials
231
58 Phase 3, 14 recruiting
FAERS reports
58,351
48,491 serious, 8,442 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )]. Venlafaxine Extended-Release Tablets are not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 )]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Venlafaxine Extended-Release Tablets are not approved for use in pediatric patients ( 8.4 )
What it is approved for
From the label in effect Oct 9, 2025.
Venlafaxine Extended-Release Tablets are indicated in adults for the treatment of: Major depressive disorder (MDD) Generalized Anxiety Disorder (GAD) Venlafaxine Extended-Release Tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) ( 1 ) Generalized Anxiety Disorder (GAD) ( 1 )
Mechanism: The mechanism of action of venlafaxine in treatment of MDD and GAD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake of serotonin and norepinephrine.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 29, 2022 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LetterLabelMedication Guide
- Jun 29, 2022 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LetterLabelMedication Guide
1 products under this application
- VENLAFAXINE BESYLATE · VENLAFAXINE BESYLATE EQ 112.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Venlafaxine" as an intervention, any sponsor and status, largest first.
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01436149 · 1,262 participants · Start Oct 27, 2011 · Primary completion Dec 23, 2013
Drug: SPD489 (Lisdexamfetamine dimesylate ); Placebo · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Carson, California; Irvine, California · 85 sites in all
- Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed PatientsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00474708 · 1,151 participants · Start Apr 2007 · Primary completion Mar 2008
Drug: Effexor; SSRI · For: Major Depressive Disorder
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 26 sites in all
- A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03538691 · 1,149 participants · Start Jul 13, 2018 · Primary completion Jul 8, 2022
Drug: Brexpiprazole; Antidepressant therapy · For: Major Depressive Disorder
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,903
- toxicity to various agents3,736
- fatigue3,326
- nausea3,255
- off label use2,815
- completed suicide2,791
- drug interaction2,670
- headache2,617
- dizziness2,416
- diarrhoea2,171
- depression2,082
- anxiety2,044
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 77 |
| 2005 | 76 |
| 2006 | 13 |
| 2007 | 3 |
| 2008 | 31 |
| 2009 | 236 |
| 2010 | 656 |
| 2011 | 985 |
| 2012 | 1,428 |
| 2013 | 1,551 |
| 2014 | 1,842 |
| 2015 | 2,808 |
| 2016 | 3,305 |
| 2017 | 3,771 |
| 2018 | 4,883 |
| 2019 | 5,378 |
| 2020 | 5,208 |
| 2021 | 4,467 |
| 2022 | 4,129 |
| 2023 | 4,709 |
| 2024 | 4,784 |
| 2025 | 4,549 |
| 2026 | 3,461 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, et al. · Control Clin Trials 2004 · Clinical Trial, Multicenter Study
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis.
Henssler J, Schmidt Y, Schmidt U, et al. · Lancet Psychiatry 2024 · Systematic Review, Meta-Analysis
- The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Mansoor B, Rengasamy M, Hilton R, et al. · J Child Adolesc Psychopharmacol 2013 · Multicenter Study, Randomized Controlled Trial
- Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA, Cipriani A, Cowen PJ, et al. · Lancet Psychiatry 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G, Meader N, Barbui C, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.